Pivotal Trial Shows TransCon CNP's Durable Two-Year Benefits in Achondroplasia
ASND sits 85% above its 52-week low of $124.06.
Summary
Ascendis Pharma announced new two-year data from its pivotal ApproaCH Trial for TransCon CNP (navepegritide), marketed as YUVIWEL®, in children with achondroplasia. The data demonstrated consistent improvements in growth and further improvement in body proportionality through Week 104, with the drug generally well-tolerated. This positive long-term efficacy and safety data strengthens the commercial profile of YUVIWEL, which received U.S. FDA approval in February 2026. The durable benefits are crucial for physician confidence and market adoption, and also support the ongoing European Medicines Agency review, with a decision anticipated in Q4 2026. Traders will watch for updates on European approval and initial sales traction in the U.S.
At the time of this announcement, ASND was trading at $229.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9B. The 52-week trading range was $124.06 to $248.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.